For decades, the question of whether statins are worth it for healthy older adults with no prior heart disease has been hotly debated. Now, the STAREE trial — the largest randomized study of its kind — has delivered a clear answer: yes, at least for cardiovascular protection. Daily atorvastatin 40 mg reduced the composite risk of cardiovascular death, nonfatal heart attack or stroke, and coronary revascularization by 30% compared to placebo over nearly six years in nearly 10,000 adults aged 70 and older.

The benefits were consistent across age groups, LDL levels, blood pressure, BMI, and kidney function — and held up despite real-world challenges like dropouts and dose changes. That said, statins didn't move the needle on disability-free survival (combining death from any cause, dementia, or persistent physical disability), leaving some nuance for clinicians to weigh.

By the Numbers:

• 10.9 vs. 15.5 cardiovascular events per 1,000 person-years (atorvastatin vs. placebo); HR 0.70
• LDL cholesterol dropped 48 mg/dL in the statin group vs. 16 mg/dL in the placebo group
• Serious adverse events were equal between groups at 2.7%, though small excesses in musculoskeletal, liver, and diabetes-related events were noted with statins
• Only 55.6% of statin patients were still taking the drug at 5 years

Why it matters: These results could reshape prescribing guidelines for older adults, a population previously given only a weak recommendation for statins. Researchers are urging guideline bodies to act — and are calling for more studies on higher doses and combination therapies.